LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Smith & Nephew PLC ADR

Geschlossen

36.14 1.92

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.86

Max

36.16

Schlüsselkennzahlen

By Trading Economics

Einkommen

296M

Verkäufe

3B

KGV

Branchendurchschnitt

31.586

121.746

Dividendenrendite

2.17

Gewinnspanne

9.895

Angestellte

17,000

EBITDA

723M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-4.75% downside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.17%

2.26%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

15B

Vorheriger Eröffnungskurs

34.22

Vorheriger Schlusskurs

36.14

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Smith & Nephew PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Feb. 2026, 23:21 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15. Feb. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15. Feb. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15. Feb. 2026, 23:06 UTC

Ergebnisse

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15. Feb. 2026, 23:04 UTC

Ergebnisse

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15. Feb. 2026, 23:01 UTC

Ergebnisse

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Shareholders to Receive A$5.20/Share in Cash

15. Feb. 2026, 22:52 UTC

Akquisitionen, Fusionen, Übernahmen

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO Tania Archibald Speaking on a Call With Media

15. Feb. 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15. Feb. 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15. Feb. 2026, 22:14 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15. Feb. 2026, 20:48 UTC

Ergebnisse

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15. Feb. 2026, 20:47 UTC

Ergebnisse

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15. Feb. 2026, 20:46 UTC

Ergebnisse

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15. Feb. 2026, 20:45 UTC

Ergebnisse

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15. Feb. 2026, 20:44 UTC

Ergebnisse

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15. Feb. 2026, 20:43 UTC

Ergebnisse

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope Net Debt A$2.2 Million at Dec. 31

15. Feb. 2026, 20:42 UTC

Ergebnisse

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15. Feb. 2026, 20:41 UTC

Ergebnisse

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15. Feb. 2026, 20:40 UTC

Ergebnisse

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15. Feb. 2026, 20:39 UTC

Ergebnisse

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer-Vergleich

Kursveränderung

Smith & Nephew PLC ADR Prognose

Kursziel

By TipRanks

-4.75% Nachteil

12-Monats-Prognose

Durchschnitt 34.46 USD  -4.75%

Hoch 34.91 USD

Tief 34 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Smith & Nephew PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

2 ratings

0

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

26.64 / 28.37Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat